CardioPrecision Ltd, the global leader in transcervical access for the treatment of structural heart disease and cardiothoracic interventions, received further investment. The equity financing was led by existing investors and the Scottish Investment Bank, the investment arm of Scottish Enterprise.

CardioPrecision’s patented CoreVista® Technology facilitates access to the chest through a short incision in the skin crease of the neck, potentially facilitating a wide range of cardiothoracic and cardiovascular interventions with multi-billion dollar estimated global market potential.

Success in raising funds during the global COVID-19 pandemic is a testament to investors’ confidence in the Company. This investment will allow the Company to continue its path towards introduction of its CE-marked products to the market.

“We are extremely pleased to have secured this further investment and remain confident in  our ability to provide innovative, minimally invasive treatment options for patients with structural heart disease. During these challenging times,  we would also like to express sincere gratitude to our clinician partners in the global health care community for their tireless dedication in serving patients. “ said CardioPrecision Founder and Chief Executive Officer, Dr Ying Sutherland, PhD.

“CardioPrecision will continue to develop new high growth market opportunities using the enabling CoreVista® Technology platform, There are exciting prospects for the Company to apply its disruptive technology and unique minimally invasive approach to a variety of existing cardiovascular procedures, thus delivering significant benefits for patients and their physicians.” commented CardioPrecision Founder and Chief Medical Officer, Dr Fraser Sutherland, MD.

Quest Corporate Ltd served as corporate financial advisor to CardioPrecision Ltd.

About CardioPrecision Ltd

CardioPrecision Ltd, based in Glasgow, UK is the global leader in transcervical access for the treatment of structural heart disease and cardiothoracic interventions.  CardioPrecision’s CoreVista® Retractor and Accessories allows cardiothoracic surgery to be performed through a short incision in the skin crease of the neck. CardioPrecision is dedicated to making patients’ lives better through the development of innovative, less invasive access solutions for cardiothoracic surgery and cardiovascular interventions.  For more information, visit

About Quest Corporate Ltd

Quest is a Corporate Finance Boutique based in Edinburgh. Quest takes a unique approach to corporate transactions, offering a results focused service that balances  experience and market knowledge with the client business’s requirements. For more information, visit


This news release includes forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding expected product benefits, anticipated product approvals, future plans related to the product lines, the benefits of the transaction, including future financial and operating results, objectives and expectations and other statements that are not historical facts. Such statements are based on the views and assumptions of the management of the company and are subject to significant risks and uncertainties. 

Actual future events or results may differ materially from these statements as a result of various factors, including: unexpected costs of device development and approvals, unanticipated outcomes after more expanded pre-clinical and clinical experience with the devices, unexpected changes or delays related to product supply, potentials for unexpected regulatory or quality delays or developments, competitive dynamics, global economic conditions and customer acceptance, and other economic, business, and/or competitive factors. The forward-looking statements speak only as of the date of this communication. Except as required by law, The Company undertakes no obligation to update these statements.

CoreVista is a trademark of CardioPrecision Ltd.